BFS
PTGX icon

Bare Financial Services’s Protagonist Therapeutics PTGX Stock Holding History

Bare Financial Services’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.8K Buy
186
+91
+96% +$9.51K 0.01% 229
2026
Q1 		$10K Sell
95
-15
-14% -$1.33K ﹤0.01% 344
2025
Q4 		$9.61K Buy
110
+76
+224% +$6.22K ﹤0.01% 260
2025
Q3 		$2.26K Buy
34
+11
+48% +$625 ﹤0.01% 783
2025
Q2 		$1.27K Buy
+23
New +$1.1K ﹤0.01% 843

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bare Financial Services's PTGX Position: Q2 2026 in Review

Bare Financial Services increased its Protagonist Therapeutics (PTGX) stake by 96% in Q2 2026, buying an estimated $9.51K and bringing the position to 186 shares worth $22.8K. The position accounts for 0.01% of the portfolio, ranked #229.

Bare Financial Services first reported a position in PTGX in Q2 2025 and has held it in 5 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Bare Financial Services held 186 shares of Protagonist Therapeutics worth $22.8K as of Q2 2026.
  • Bare Financial Services bought 91 Protagonist Therapeutics shares in Q2 2026, an estimated $9.51K.
  • Protagonist Therapeutics made up 0.01% of Bare Financial Services's portfolio in Q2 2026, its #229 holding.
  • Bare Financial Services first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.